Boehringer Ingelheim to acquire Amgen facility
Strengthens BI position in biologics
Boehringer Ingelheim of Germany is to expand its contract manufacturing business by taking over the rights in and substantially all assets at Amgen's Fremont California pharmaceutical manufacturing facility.
The 100,000ft2 Fremont facility currently employs approximately 360 people, who will join Boehringer Ingelheim.
US biotech Amgen acquired the Fremont facility when it took over Abgenix in 2006.
Boehringer Ingelheim Board of Managing Directors’ Wolfram Carius said the technological expertise at Fremont and the state-of-the-art facility would enable the company to further strengthen its global contract manufacturing business including new biological entity process development and manufacturing efforts.
The transaction is expected to close in March.
Boehringer Ingelheim has been a contract manufacturer for Amgen for more than ten years.
Amgen will continue to have a presence in the San Francisco Bay Area through its South San Francisco facility, one of its key research centres.
